AM-PHARMA TO PRESENT DATA FROM PHASE 3 REVIVAL STUDY AT UPCOMING SCIENTIFIC CONFERENCES

/in , , /by

Principal investigator Professor Peter Pickkers to present data at ISICEM on March 21st in Brussels and at the AKI & CRRT conference on March 29th in San Diego  A significant reduction in major adverse kidney events by day 90 and no difference in 28-day all-cause mortality was observed after review of the data from all […]

Read more

Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury

/in /by

You can read the whole publication by clicking on this button View publication

Read more

Effects of a human recombinant alkaline phosphatase during impaired mitochondrial function in human renal proximal tubule epithelial cells

/in /by

View publication

Read more

Effects of a human recombinant alkaline phosphatase on renal hemodynamics, oxygenation and inflammation in two models of acute kidney injury

/in /by

View publication

Read more

Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI)

/in /by

View publication

Read more

Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers

/in /by

View publication

Read more

Improvement of the skeletal and dental hypophosphatasia phenotype in Alpl−/− mice by administration of soluble (non-targeted) chimeric alkaline phosphatase

/in /by

View publication

Read more